• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Drug Products
  • All Drug Products
  • A Phase I, open-label, randomized, two way crossover pharmacokinetic study comparing the bioavailability of acetylsalicylic acid (ASA) after 5 days repeated once daily administration of a fixed dose combination capsule of ASA 81 mg/esomeprazole 20 mg and ASA 80 mg (European aspirin reference product) in Healthy Male and Female Volunteers

Disease
pharmacokinetics
Drug Name
Nexium
Generic Name
Esomeprazole
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
I
Start Date
Nov 3, 2011
Study Name
D961FC00012
Study Id
D961FC00012
ClinicalTrials.gov ID
NCT01448031
Recruiting Status
Closed
Protocol Status
Not Available
Report
Sep 28, 2012
  • D961FC00012.pdf (539 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013